Coşkun DOĞAN, Nesrin KIRAL, Elif TORUN PARMAKSIZ, Ali FİDAN, Sevda ŞENER CÖMERT, Benan ÇAĞLAYAN, Berrin ZİNNET ERASLAN

Küçük Hücreli Dışı Akciğer Kanserlerinde PET-BT’de Ölçülen Suvmax Değerinin Evre ve Sağ Kalım ile İlişkisi

Amaç:Küçük hücreli dışı akciğer kanserlerinde (KHDAK), pozitron emisyon tomografi-bilgisayarlı tomografide (PET-BT) ölçülen maksimum standart uptake (SUVMax) değerlerinin evre ve sağ kalım ile ilişkisi araştırmak.Yöntem: Çalışmaya 2014-2017 yılları arasında KHDAK tanısı alan olgular dahil edildi. Olgular erken evre (Evre 1-2) ve lokal ileri/ileri (Evre 3-4) olarak iki gruba ayrıldı. Olguların demografik-radyolojik özellikleri, kanser histopatolojileri, evreleri, PET-BT’de raporlanan SUVMax değerleri, ölen hastaların ulusal ölüm bildirim sisteminden ölüm zamanları kayıt edildi. İki grubun verileri birbirleri ile karşılaştırıldı.Bulgular:Çalışmaya 133’ü (%46.3) erken evre, 154’ü (%53.7) lokal ileri/ileri olan 287 olgu dahil edildi. Erken evre KHDAK olgularda ortalama SUVMax değeri 14.5 iken, ileri evre olgularda 16.8’di (p=0.034). PET-BT’de SUVMax değeri 12 ve üstünde raporlanan olguların (n=101) median sağ kalımı 15±1.4 ay iken, 11 ve altında raporlanan olguların (n=186) median sağ kalımı 25±3.1 aydı (p=0.046). Yapılan lojistik regresyon modelinde tümör SUVMax değerinin tek başına sağ kalıma istatistiksel anlamlı bir etkisi yoktu (p=0.332).Sonuç:Düşük SUVMax değerleri ile erken evre KHDAK’lar arasında bir ilişki vardır. Görece düşük SUVMax değerleri sağ kalımla ilişkili görünmekle birlikte, tek başına sağ kalıma etkisi tartışmalıdır.

The Association of the SUVMax Value Measured on PET-CT with the Stage and Survival in Nonsmall Cell Lung Cancers

Objective:To investigate the association of the maximum standard uptake (SUVmax) levels measured on positron emission tomography-computed tomography (PET-CT) with the stage and survival in non-small cell lung cancers (NSCLC).Method:Patients diagnosed as having NSCLC between 2014 and 2017 were included in the study. Patients were divided into two groups as the early stage (Stage 1-2), and locally advan-ced/advanced stage (Stage 3-4) disease. The demographic-radiologic features, cancer histopat-hologies, stage, the SUVMax levels reported on PET-CT, the time of death of the patients from the national death reporting system were recorded. The data of two groups were compared.Results:A total of 287 patients including 133 (46.3%) patients in the early stage, and 154 patients (53.7%) in the locally advanced/advanced stage were included in the study. The mean SUVMax value was 14.5 in early stage NSCLC patients, and the SUVMax value was 16.8 in patients with the advanced stage disease (p: 0.034). The median survival was 15±1.4 months of the patients (n:101) whose SUVMax value was reported as 12 and above on PET-CT, and the median survival of the patients (n:186) whose SUVMax value was reported as 11 and below was 25±3.1 months (p:0.046). The logistic regression model showed that the tumor SUVMax value alone had no statistically significant effect on survival (p:0.332).Conclusion:There is an association between the lower SUVMax values and early stage NSCLCs. Although the relatively lower SUVMax values seemed to be associated with survival, its effect on survival alone was controversial.

PDF

___

1.T.C Sağlık Bakanlığı. Türkiye Halk sağlığı Kurumu. Türkiye Kanser İstatistikleri. http://kanser.gov.tr/Dosya/ca_istatistik/2014-RAPOR._uzun.pdf (Erişim tarihi: 30 Haziran 2017)
2.Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin 2017;67:7-30.https://doi.org/10.3322/caac.21387
3.Finkelstein DM, Ettinger DS, Ruckdeschel JC. Long-term survivors in metastatic non - small - cell lung cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol. 1986;4:702-9 htttps://doi.org/10.1200/JCO.1986.
4.5.7024.Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355:983-91.https://doi.org/10.1056/NEJMoa060570
5.Yıldırım F, Türk M, Akdemir ÜÖ, Yurdakul AS, Öztürk C. The relationship between primary tumor metabolic activ-ity and lymph node and distant organ metastasis in non-small cell lung cancer. Gazi Medical Journal 2018;29:164-8.
6.Akdemir ÜÖ, Aydos U. Role of Fluorodeoxyglucose Positron emission tomography/computed tomography imaging in diagnosis and staging of lung cancer. Nucl Med Semin 2018;4:6-17.https://doi.org/10.4274/nts.2018.002
7.Erdem V, Şen HS, Kömek H, Tanrıkulu AÇ, Abakay A, Sezgi C, Kaya H, Şenyiğit A. Küçük hücreli dışı akciğer kanseri olan olgularda prognostik faktörler ve PET/BT’deki SUV max değerinin prognostik önemi. Tuberk Toraks 2012;60(3):207-17.https://doi.org/10.5578/tt.3062
8-.u-Yu Lua YY, Jin-Hua Chene JH, Liang JA, Chu S, Lin WY, Kao CH. 18F-FDG PET or PET/CT for detecting extensive disease in small-cell lung cancer: a systematic review and meta-analysis Nuclear Medicine Communications 2014;35:697-703.https://doi.org/10.1097/MNM.0000000000000122
9.Cox BL, Mackie TR, Eliceiri KW. The sweet spot: FDG and other 2-carbon glucose analogs for multi-modal meta-bolic imaging of tumor metabolism. Am J Nucl Med Mol Imaging 2014;5:1-13.
10.Uğurluer G, Atalar B, İkizler HAS, Sözer N, Kibar M, Serin M, ve ark. Serviks kanserli hastalarda PET/BT Tetkikinde Primer Tümörün FDG Tutulum Derecesi ile Lenf Nodu Metastazı Arasındaki İlişki. ACU Sağlık Bil Derg. 2016;3:129-33.
11.Ung YC, Maziak DE, Vanderveen JA, Smith CA, Gulenchyn K, Lacchetti C, Evans WK; Lung Cancer Disease Site Group of Cancer Care Ontario’s Program in Evidence-Based Care. 18 Fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lungcancer: a systematic review. J Natl Cancer Inst. 2007;99:1753-67.https://doi.org/10.1093/jnci/djm232
12.Sönmezoğlu K. Akciğer kanserlerinde FDG-PET uygulamaları. Tüberküloz ve Toraks Dergisi 2005;53:94-112.
13.Hellwig D, Gröschel A, Graeter TP, Hellwig AP, Nestle U, Schafers HJ, et al. Diagnostic performance and prognos-tic impact of FDG-PET in suspected recurrence of surgi-cally treated nonsmall cell lung cancer. Eur J Nucl Med Mol Imaging 2006;33:13-21. https://doi.org/10.1007/s00259-005-1919-4
14.Domachevsky L, Groshar D, Galili R, Saute M, Bernstine H. Survival prognostic value of morphological and meta-bolic variables in patients with stage I and II non-small cell lung Cancer. Eur Radiol. 2015;25(11):3361-7.https://doi.org/10.1007/s00330-015-3754-8
15.Cistaro A, Quartuccio N, Mojtahedi A, Fania P, Filosso PL, Campenni A, Ficola U, Baldari S. Prediction of 2 years-survival in patients with stage I and II non-small cell lung cancer utilizing (18)F-FDG PET/CT SUV quantification. Radiol Oncol. 2013;47(3):219-23.https://doi.org/10.2478/raon-2013-0023
16.Kwon W, Howard BA, Herndon JE, Patz EF Jr. FDG Uptake on positron emission tomography correlates with sur-vival and time to recurrence in patients with Stage I Non-Small-Cell Lung Cancer. J Thorac Oncol. 2015;10:897-902.https://doi.org/10.1097/JTO.0000000000000534
17.Li M, Liu N, Hu M, Shi F, Yuan S, Zhang P, Fu Z, Yang G, Yu J. Relationship between primary tumor fluorodeoxyg-lucose uptake and nodal or distant metastases at presen-tation in T1 stage non-small cell lung cancer. Lung Cancer. 2009;63(3):383-6.https://doi.org/10.1016/j.lungcan.2008.06.004
18.Cerfolio RJ, Bryant AS, Ohja B, Bartolucci AA. The maxi-mum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. J Thorac Cardiovasc Surg. 2005;130(1):151-9.https://doi.org/10.1016/j.jtcvs.2004.11.007
19.Younes M, Brown R.W, Stephenson M, et al. Overexpression of Glut-1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer. 1997;80:1046-51.https://doi.org/10.1002/(SICI)1097-0142(19970915) 80:6<1046::AID-CNCR6>3.0.CO;2-7
20.Nambu A, Kato S, Sato Y, Okuwaki H, Nishikawa K, Saito A, Matsumoto K, Ichikawa T, Araki T. Relationship between maximum standardized uptake value (SUVmax) of lung cancer and lymph node metastasis on FDG-PET. Ann Nucl Med. 2009;23:269-75.https://doi.org/10.1007/s12149-009-0237-5
21.Bury T, Dowlati A, Paulus P. Whole-body 18FDG positron emission tomography in the staging of non-small cell lung cancer. Eur Respir J 1997;10:2529-34.https://doi.org/10.1183/09031936.97.10112529
22.Lu P, Yu L, Li Y, Sun Y. A correlation study between maximum standardized uptake values and pathology and clinical staging in nonsmall cell lung cancer. Nucl Med Commun 2010;31:646-51.https://doi.org/10.1097/MNM.0b013e328339bddb
23.Liu J, Dong M, Sun X, Li W, Xing L, Yu J. Prognostic Value of 18F-FDG PET/CT in Surgical non-small cell .ung Cancer: A Meta-Analysis. PLoS One. 2016;11(1):e0146195.https://doi.org/10.1371/journal.pone.0146195
24.Ahuja V, Coleman RE, Herndon J, Patz EF Jr. The prognos-tic significance of fluorodeoxyglucose PET imaging for patients with nonsmall cell lung carcinoma. Cancer 1998;83:918-24.https://doi.org/10.1002/(SICI)1097-0142(19980901)83: 5<918::AID-CNCR17>3.0.CO;2-Y25-Nael S, Kathy G, Julie L, Rashid A, Kishore D, Lorraine W, Eillish M, Vincent Y. Clinical implication and prognostic significance of standardised uptake value of primary non-small cell lung cancer on positron emissıon tomography: analysis of 176 case .European Journal of Cardiothoracic Surgery 2008;34:892-97.https://doi.org/10.1016/j.ejcts.2008.07.023
26.Berghmans T, Dusart M, Paesmans M, Hossein-Foucher C, Buvat I, Castaigne C, Scherpereel A, et al; European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose posi-tron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol. 2008;3(1):6-12.https://doi.org/10.1097/JTO.0b013e31815e6d6b
27.Vesselle H, Freeman JD, Wiens L, Stern J, Nguyen HQ, HawesSE. Fluorodeoxy glucose uptake of primary non-smallcell lung cancer at positron emission tomography: new contrary data on prognostic role. Clin Cancer Res 2007;13: 255-63.https://doi.org/10.1158/1078-0432.CCR-06-1128
28.Yalçınkaya E, Anar C, Yavuz MY, Ünsal İ, Güldaval F, Derya K, Halilçolar H. Küçük hücreli dışı akciğer kanseri olgularında PET/BT’deki primer tümör SUVMax değerinin prognostik değeri ve uzak organ lenf nodu metastazı ile ilişkisi. İzmir Göğüs Hastanesi Dergisi. 2015;29(3):127-137.
29.Araz M, Soydal C, Özkan E, Sen E, Nak D, Kucuk ON, Gönüllü U, Kir KM. Prognostic value of metabolic param-eters on baseline 18F-FDG PET/CT in small cell lung can-cer. Q J Nucl Med Mol Imaging. 2019. [Epub ahead of print].
30.Li X, Wang D, Yu L. Prognostic and Predictive Values of Metabolic Parameters of 18F-FDG PET/CT in patients with cchemotherapy. Mol Imaging. 2019;18:1536012119846025.https://doi.org/10.1177/1536012119846025
31.Long NM, Smith CS. Causes and imaging features of false positives and false negatives on F-PET/CT in oncologic imaging. 2011;6:679-98.https://doi.org/10.1007/s13244-010-0062-3